Modalis accomplishes gene activation, while Tune achieves gene repression, both in non-human primates

Start-ups are tuning gene expression by hitching a range of effector domains to catalytically dead CRISPR machinery

Sweden's MD Pharma targeting autophagy in congenital muscular dystrophy